U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

OnabotulinumtoxinA for Injection (Botox): For the Prophylaxis of Headaches in Adults With Chronic Migraine (≥ 15 Days per Month With Headache Lasting 4 Hours a Day or Longer) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.

Cover of OnabotulinumtoxinA for Injection (Botox)

OnabotulinumtoxinA for Injection (Botox): For the Prophylaxis of Headaches in Adults With Chronic Migraine (≥ 15 Days per Month With Headache Lasting 4 Hours a Day or Longer) [Internet].

Show details

Pharmacoeconomic Review Report

DrugonabotulinumtoxinA for injection (Botox)
IndicationFor the prophylaxis of headaches in adults with chronic migraine (≥ 15 days per month with headache lasting 4 hours a day or longer)
Listing requestProphylaxis of headaches in adults with chronic migraine (≥ 15 days per month with headache lasting 4 hours a day or longer) who have failed (i.e., lack of efficacy, intolerance, or clinical contraindication) ≥ 3 prior oral prophylactic medications.

Patients who have not obtained an adequate treatment response (≥ 30% reduction in days of headache per month) after 2 treatment cycles should be discontinued from further therapy.
ManufacturerAllergan Inc.

ABBREVIATIONS

EXECUTIVE SUMMARY OF THE PHARMACOECONOMIC SUBMISSION

1. INTRODUCTION

2. METHODS

3. RESULTS

4. DISCUSSION

5. CONCLUSIONS

APPENDIX 1 COST COMPARISON TABLE

APPENDIX 2 SUMMARY OF KEY OUTCOMES

APPENDIX 3 ADDITIONAL INFORMATION

APPENDIX 4 SUMMARY OF CLINICAL INFORMATION

APPENDIX 5 OTHER HEALTH TECHNOLOGY ASSESSMENT FINDINGS

REFERENCES

Copyright © CADTH 2015.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK344299

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this page (1.1M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...